List of Lamictal Xr drug patents

Lamictal Xr is owned by Glaxosmithkline Llc.

Lamictal Xr contains Lamotrigine.

Lamictal Xr has a total of 2 drug patents out of which 0 drug patents have expired.

Lamictal Xr was authorised for market use on 29 May, 2009.

Lamictal Xr is available in tablet, extended release;oral dosage forms.

The generics of Lamictal Xr are possible to be released after 14 June, 2028.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9144547 GLAXOSMITHKLINE LLC Oral dosage form for controlled drug release
Sep, 2023

(7 months from now)

US8637512 GLAXOSMITHKLINE LLC Formulations and method of treatment
Jun, 2028

(5 years from now)

Drugs and Companies using LAMOTRIGINE ingredient

Market Authorisation Date: 29 May, 2009

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of LAMICTAL XR before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in